Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor

Lance T. Piecoro, Daniel P. Wermeling, Frederick A. Schmitt, J. Wesson Ashford

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. In both patients seizures were associated with discontinuation of short-term agents with high antimuscarinic properties. Hence, abrupt discontinuation of antimuscarinics or anticholinergics with high antimuscarinic properties in patients receiving long-term acetylcholinesterase inhibition therapy may be associated with a reduction of seizure threshold. With increasing administration of acetylcholinesterase inhibitors for patients with Alzheimer's disease, practitioners should be aware of the potential for drug-drug interactions and other complications. In general, it is good medical practice to avoid concomitant administration with centrally acting anticholinergic agents.

Original languageEnglish
Pages (from-to)1129-1132
Number of pages4
Issue number5
StatePublished - Sep 1998

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor'. Together they form a unique fingerprint.

Cite this